BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 27329402)

  • 1. Adjuvant chemotherapy with tegafur/uracil for more than 1 year improves disease-free survival for low-risk Stage II colon cancer.
    Hu JM; Chou YC; Wu CC; Hsiao CW; Lee CC; Chen CT; Hu SI; Liu WT; Jao SW
    J Chin Med Assoc; 2016 Sep; 79(9):477-88. PubMed ID: 27329402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral tegafur-uracil as metronomic therapy following intravenous FOLFOX for stage III colon cancer.
    Huang WY; Ho CL; Lee CC; Hsiao CW; Wu CC; Jao SW; Yang JF; Lo CH; Chen JH
    PLoS One; 2017; 12(3):e0174280. PubMed ID: 28328969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial.
    Matsuda C; Ishiguro M; Teramukai S; Kajiwara Y; Fujii S; Kinugasa Y; Nakamoto Y; Kotake M; Sakamoto Y; Kurachi K; Maeda A; Komori K; Tomita N; Shimada Y; Takahashi K; Kotake K; Watanabe M; Mochizuki H; Nakagawa Y; Sugihara K;
    Eur J Cancer; 2018 Jun; 96():54-63. PubMed ID: 29677641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of oral tegafur-uracil as maintenance therapy following intravenous 5-fluorouracil chemotherapy in stage III colon cancer.
    Hong KD; Lee SI; Moon HY
    Hepatogastroenterology; 2012; 59(113):104-7. PubMed ID: 22251527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stage III Colon Cancer: The Individualized Strategy of Adjuvant Chemotherapy for Aged Under and Over 70.
    Lu CS; Chang PY; Chen YG; Chen JH; Wu YY; Ho CL
    PLoS One; 2015; 10(9):e0138632. PubMed ID: 26382962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.
    Lembersky BC; Wieand HS; Petrelli NJ; O'Connell MJ; Colangelo LH; Smith RE; Seay TE; Giguere JK; Marshall ME; Jacobs AD; Colman LK; Soran A; Yothers G; Wolmark N
    J Clin Oncol; 2006 May; 24(13):2059-64. PubMed ID: 16648506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective observational study of the efficacy of oral uracil and tegafur plus leucovorin for stage II colon cancer with risk factors for recurrence using propensity score matching (JFMC46-1201).
    Sadahiro S; Sakamoto K; Tsuchiya T; Takahashi T; Ohge H; Sato T; Kondo K; Ogata Y; Baba H; Itabashi M; Ikeda M; Hamada M; Maeda K; Masuko H; Takahashi K; Sakamoto J; Kusano M; Hyodo I; Taguri M; Morita S
    BMC Cancer; 2022 Feb; 22(1):170. PubMed ID: 35168560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant chemotherapy increase survival and decrease recurrence in stage IIA colon cancer.
    Yun HR; Kim HC; Yun SH; Lee WY
    Hepatogastroenterology; 2012; 59(120):2466-71. PubMed ID: 23169179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance tegafur-uracil versus observation following an adjuvant oxaliplatin-based regimen in patients with stage III colon cancer after radical resection: study protocol for a randomized controlled trial.
    Yeh YS; Tsai HL; Huang CW; Wei PL; Sung YC; Tang HC; Wang JY
    Trials; 2017 Apr; 18(1):191. PubMed ID: 28441966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase III trial of treatment duration for oral uracil and tegafur plus leucovorin as adjuvant chemotherapy for patients with stage IIB/III colon cancer: final results of JFMC33-0502.
    Sadahiro S; Tsuchiya T; Sasaki K; Kondo K; Katsumata K; Nishimura G; Kakeji Y; Baba H; Sato S; Koda K; Yamaguchi Y; Morita T; Matsuoka J; Usuki H; Hamada C; Kodaira S
    Ann Oncol; 2015 Nov; 26(11):2274-80. PubMed ID: 26347106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term survival results of surgery alone versus surgery plus UFT (Uracil and Tegafur)-based adjuvant therapy in patients with stage II colon cancer.
    Lin BR; Lai HS; Chang TC; Lee PH; Chang KJ; Liang JT
    J Gastrointest Surg; 2011 Dec; 15(12):2239-45. PubMed ID: 21993974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized controlled trial of the efficacy of adjuvant immunochemotherapy and adjuvant chemotherapy for colorectal cancer, using different combinations of the intracutaneous streptococcal preparation OK-432 and the oral pyrimidines 1-hexylcarbamoyl-5-fluorouracil and uracil/tegafur.
    Watanabe M; Nishida O; Kunii Y; Kodaira S; Takahashi T; Tominaga T; Hojyo K; Kato T; Niimoto M; Kunitomo K; Isomoto H; Ohashi Y; Yasutomi M
    Int J Clin Oncol; 2004 Apr; 9(2):98-106. PubMed ID: 15108041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncologic Outcomes of Oral Adjuvant Chemotherapy Regimens in Stage III Colon Cancer: Tegafur-Uracil Plus Leucovorin Versus Capecitabine.
    Tashiro J; Yamaguchi S; Ishii T; Kondo H; Hara K; Shimizu H; Takemoto K; Suzuki A
    Clin Colorectal Cancer; 2017 Sep; 16(3):e141-e145. PubMed ID: 28216247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
    André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
    J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit of Uracil-Tegafur Used as a Postoperative Adjuvant Chemotherapy for Stage IIA Colon Cancer.
    Chen PH; Jhou HJ; Chung CH; Wu YY; Huang TC; Lee CH; Chien WC; Chen JH
    Medicina (Kaunas); 2022 Dec; 59(1):. PubMed ID: 36676634
    [No Abstract]   [Full Text] [Related]  

  • 16. Inferior oncological prognosis of surgery without oral chemotherapy for stage III colon cancer in clinical settings.
    Tashiro J; Yamaguchi S; Ishii T; Suzuki A; Kondo H; Morita Y; Hara K; Koyama I
    World J Surg Oncol; 2014 May; 12():145. PubMed ID: 24884880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial.
    Akasu T; Moriya Y; Ohashi Y; Yoshida S; Shirao K; Kodaira S;
    Jpn J Clin Oncol; 2006 Apr; 36(4):237-44. PubMed ID: 16675478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of oral tegafur-uracil as metronomic therapy following concurrent chemoradiotherapy in patients with non-distant metastatic TNM stage IV nasopharyngeal carcinoma.
    Chen JH; Huang WY; Ho CL; Chao TY; Lee JC
    Head Neck; 2019 Nov; 41(11):3775-3782. PubMed ID: 31435974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy.
    An MS; Yoo JH; Kim KH; Bae KB; Choi CS; Hwang JW; Kim JH; Kim BM; Kang MS; Oh MK; Hong KH
    World J Surg Oncol; 2015 Feb; 13():64. PubMed ID: 25889520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
    Gill S; Loprinzi CL; Sargent DJ; Thomé SD; Alberts SR; Haller DG; Benedetti J; Francini G; Shepherd LE; Francois Seitz J; Labianca R; Chen W; Cha SS; Heldebrant MP; Goldberg RM
    J Clin Oncol; 2004 May; 22(10):1797-806. PubMed ID: 15067028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.